Bhattarai Abhinav, Dhakal Garima, Shah Sangam, Subedi Aastha, Sah Sanjit Kumar, Mishra Shyam Kumar
Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Maharajgunj 44600, Nepal.
Central Department of Public Health, Institute of Medicine, Tribhuvan University, Maharajgunj 44600, Nepal.
Interdiscip Perspect Infect Dis. 2022 Jun 6;2022:8508489. doi: 10.1155/2022/8508489. eCollection 2022.
The Centers for Disease Control and Prevention (CDC) identifies asthma as a comorbidity in COVID-19 that increases the risk of severity and death. However, research has shown that asthma is not associated with increased severity and death, thus making the consequences of asthma in COVID-19 unclear.
We searched the electronic databases PubMed, WHO COVID-19 database, and Taylor and Francis Online for studies that compared the medical outcomes of COVID-19 between patients with and without asthma, from the emergence of SARS-CoV-2 in December 2019 to the 3 of September 2021, excluded duplicates, reviews, editorials, and case reports, and screened the titles, abstracts, and full texts. The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS) for nonrandomized studies. Rates of intensive care unit (ICU) admission, intubation, and death among patients with and without asthma were compiled and meta-analysis was conducted using a random-effects model.
Nineteen studies with a total of 289,449 participants met the inclusion criteria. COVID-19 patients with asthma had no significant association with increased risk of ICU admission, intubation, and death as compared with those without asthma ((odds ratio (OR) = 1.25, confidence interval (CI) = 0.90-1.74, = 82%, = 55.13, < 0.01), (OR = 0.89, CI = 0.59-1.34, = 91%, = 110.82, < 0.01), and (OR = 0.90, 95% CI = 0.63-1.27, = 88%, = 146.96, < 0.01)), respectively.
Preexisting asthma did not significantly increase the risk of poorer prognosis and death from COVID-19.
美国疾病控制与预防中心（CDC）将哮喘确定为COVID-19的一种合并症，会增加病情严重程度和死亡风险。然而，研究表明哮喘与病情严重程度增加和死亡并无关联，因此COVID-19中哮喘的后果尚不清楚。
我们在电子数据库PubMed、世界卫生组织COVID-19数据库以及Taylor and Francis Online中搜索了2019年12月SARS-CoV-2出现至2021年9月3日期间，比较有哮喘和无哮喘患者COVID-19医疗结局的研究，排除重复项、综述、社论和病例报告，并筛选标题、摘要和全文。使用纽卡斯尔-渥太华量表（NOS）对纳入研究的质量进行非随机研究评估。汇总有哮喘和无哮喘患者的重症监护病房（ICU）入院率、插管率和死亡率，并采用随机效应模型进行荟萃分析。
19项研究共289,449名参与者符合纳入标准。与无哮喘的COVID-19患者相比，有哮喘的患者在ICU入院、插管和死亡风险增加方面无显著关联（（比值比（OR）=1.25，置信区间（CI）=0.90-1.74，I²=82%，τ²=55.13，P<0.01），（OR=0.89，CI=0.59-1.34，I²=91%，τ²=110.82，P<0.01），以及（OR=0.90，95%CI=0.63-1.27，I²=88%，τ²=146.96，P<0.01））。
既往哮喘并未显著增加COVID-19预后较差和死亡的风险。
